T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer
Cancer · 2026
DOI: 10.1002/cncr.70279 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer, 2026. Verfasst von Yiyang Shan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital, National Clinical Key Discipline Construction Funds, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Ovarian cancer remains a formidable therapeutic challenge due to late diagnosis, high recurrence rates, and limited treatment options. Mesothelin (MSLN) is highly expressed in ovarian cancer, making it a promising target for immunotherapy. Given this target profile, the authors developed a novel T‐cell receptor (TCR)‐like chimeric antigen receptor (CAR) T‐cell therapy targeting MSLN, designated KT127.
Methods
A first‐in‐human, dose‐escalation trial of KT127 was conducted following preclinical evaluation in vitro and in vivo. A combination of rapid titration and a standard “3 + 3” dose‐escalation design was implemented. Eleven patients received KT127 at doses ranging from 1 × 10 6 to 2 × 10 7 cells/kg following lymphodepletion. The primary objectives were to assess the safety and tolerability of KT127. Secondary objectives included overall survival, disease control rate (DCR), and progression‐free survival as efficacy measures. Quality of life (QOL) was assessed using the European Organisation for Research and Treatment of Cancer QLQ‐OV28 questionnaire.
Results
No dose‐limiting toxicities, cytokine release syndrome, or immune effector cell‐associated neurotoxicity syndrome were observed. The DCR was 80% (95% confidence interval, 44.4%–97.5%). QOL assessments indicated improvement in abdominal/gastrointestinal symptoms post‐treatment ( p = .037), with no significant deterioration in other domains. Proteomic analysis identified differential expression of kallikrein‐related peptidases (KLK13, KLK14) and chemokine CXCL17 at baseline, potentially linked to treatment outcomes.
Conclusions
This study highlights that KT127 has a manageable safety profile and shows preliminary biological activity in patients with advanced ovarian cancer, particularly those who have failed multiple lines of therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
- Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Nanjing, China.
- Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
- Nanjing CART Medical Technology Co., Ltd, Nanjing, China.
- Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Clinical Pathological Diagnosis & Research Center, Youjiang Medical University for Nationalities, Baise, China.
ORCID-Profile: Yang Shen
Förderung
- Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital
- National Clinical Key Discipline Construction Funds
- National Natural Science Foundation of China
- Major Science and Technology Projects (Life and Health) in Nanjing City
- China Postdoctoral Science Foundation
- Nanjing Postdoctoral Research Foundation Project
- Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Shan, Y., Ding, B., Ji, F., Lin, H., Shi, W., Wang, E., Wang, C., & Shen, Y. (2026). T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer. Cancer. https://doi.org/10.1002/cncr.70279
Vancouver
Shan Y, Ding B, Ji F, Lin H, Shi W, Wang E, et al. T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer. Cancer. 2026. doi:10.1002/cncr.70279
BibTeX
@article{Shan2026,
author = {Shan, Yiyang and Ding, Bo and Ji, Feng and Lin, Hao and Shi, Weiwei and Wang, Enxiu and Wang, Chen and Shen, Yang},
title = {T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70279}
}
EUVIMED